Recurrent In-Stent Restenosis: A Third Procedure or More Medical Therapy First
The same segment of his left anterior descending artery has narrowed a second time, inside two layers of stent already. The disagreement is about whether the next step should be another procedure or a harder look at why this segment keeps narrowing in the first place.
G.A., a 67-year-old man, has played the same eighteen holes most Saturdays for over a decade, and it's the incline on the back nine — the same three holes every time — where the tightness in his chest has started showing up again this past month. He's here for the second time with essentially the same problem: a stent placed in his mid-LAD four years ago for stable angina developed restenosis within it two years later, treated then with a second stent layered inside the first, and now, on angiography prompted by his returning symptoms, that same segment has narrowed again.
His diabetes is not incidental to why this keeps happening. Restenosis, and particularly recurrent restenosis within an already-treated stent, occurs at meaningfully higher rates in diabetic patients than in the general angioplasty population, and every time this segment is re-treated, the calculus for what a third procedure would even accomplish gets more complicated — repeat stenting inside two existing layers of metal narrows the final lumen further before it narrows again from tissue growth, and each additional procedure compounds rather than simply repeating the risk of the one before it. His lipids are well controlled and have been since his first stent; nothing about his medical therapy has obviously failed. What's changed is his exercise tolerance, dropping from playing a full round without incident to feeling it specifically on the inclines, a threshold low enough to represent real, reproducible angina rather than an ambiguous complaint. Fractional flow reserve — a pressure-wire measurement of whether the narrowing is actually flow-limiting, rather than a visual percentage alone — hasn't been checked yet, and whether it's done before deciding on a third procedure is itself part of what's being discussed.
Reviewing a second in-stent restenosis
I'd check FFR before committing to any repeat procedure. A 65 to 70 percent visual estimate in a segment already layered with two stents is exactly the kind of borderline lesion where visual assessment overstates or understates true physiologic significance, and treating a non-flow-limiting lesion with a third procedure exposes him to real periprocedural risk for a lesion that might not be causing his symptoms at all.
Agreed that FFR is reasonable, but I'd maximize his anti-anginal medical therapy in parallel rather than as a fallback only if FFR comes back negative. He's on a beta-blocker alone — no calcium-channel blocker, no ranolazine trial yet — and this is his second restenosis in the same segment. Escalating medical therapy now gives him a real chance to avoid a third procedure in a segment where each additional layer of stent makes future options progressively worse.
His glycemic control hasn't been specifically reviewed in this conversation, and it's underappreciated ground here. Poorly controlled diabetes is directly, mechanistically tied to restenosis risk — through smooth muscle proliferation and endothelial dysfunction — independent of whichever stent technique gets used. I'd recommend a formal glycemic review as part of this visit, including consideration of an SGLT2 inhibitor or GLP-1 receptor agonist — both have established cardiovascular outcome benefit in type 2 diabetes. I'd be careful about how far that gets stretched, though: neither class has been shown to reduce restenosis specifically, and intensive glucose lowering as such has never been demonstrated to prevent it either. Diabetes is a strong risk marker for this happening again; that is not the same as saying we have a drug that stops it. Treating this purely as a mechanical problem still leaves an untreated driver on the table — it just isn't a driver we can promise to switch off.
Agreed: FFR to be performed before any decision on repeat stenting, amlodipine added today for symptom control regardless of the FFR outcome, and a glycemic-control review scheduled with his diabetes care team.
Not agreed, and the reason a positive FFR result doesn't automatically settle what happens next:
Continue and escalate medical therapy alone; no procedure now.
Proceed to re-intervention, with a drug-coated balloon favored over a third stent layer specifically to avoid further luminal compromise, pending final interventional-team review.